What Is NN9838 Same as Cagrilintide? (Research Peptide Explained)

The peptide research landscape creates confusion the moment a compound transitions from internal development to public trials. Researchers find two names for one molecule, assume they're different formulations, and waste time chasing phantom distinctions. NN9838 and cagrilintide represent one compound at different disclosure stages: NN9838 was Novo Nordisk's Phase 1 and early Phase 2 designation before the company standardised nomenclature around 'cagrilintide' for late-stage publication. No structural difference exists. The 37-amino-acid sequence mimicking human islet amyloid polypeptide (IAPP) remains identical across both designations.

Our team sources peptides for researchers navigating precisely this kind of regulatory-to-scientific naming gap. The pattern repeats constantly: development codes leak into literature before marketing names solidify, and suppliers list both designations without clarifying they're the same compound.

Is NN9838 the same as cagrilintide?

Yes. NN9838 is the identical compound to cagrilintide, representing Novo Nordisk's internal development code used during early-phase trials before the standardised name 'cagrilintide' replaced it in published research. Both designations refer to a long-acting amylin analogue (a synthetic peptide mimicking human IAPP hormone) designed to slow gastric emptying and suppress appetite via central nervous system signaling. The amino acid sequence, mechanism of action, receptor binding profile, and pharmacokinetic half-life are identical. Only the public-facing nomenclature changed.

Most researchers encountering 'NN9838' assume it's a precursor molecule or modified variant. It's not. The confusion stems from pharmaceutical naming conventions: internal codes persist in early trial registries and patent filings long after marketing departments assign formal names. Cagrilintide became the dominant designation once Novo Nordisk advanced trials combining it with semaglutide under the brand name CagriSema. But legacy references to NN9838 remain embedded in literature from 2018–2020. This article covers the exact mechanism cagrilintide/NN9838 employs, why dual amylin-GLP-1 combinations outperform monotherapies in weight reduction trials, and which structural features distinguish it from native IAPP.

The Dual Identity: Why One Peptide Has Two Names

Pharmaceutical companies assign alphanumeric development codes to investigational compounds years before public disclosure. These internal designations track compounds through preclinical synthesis, toxicology screening, and Phase 1 safety trials without revealing strategic intent to competitors. NN9838 emerged in Novo Nordisk patent filings as early as 2017, describing a long-acting amylin receptor agonist with structural modifications preventing the amyloid aggregation that makes native IAPP toxic at high concentrations. By 2020, after demonstrating safety in 200+ participants across Phase 1 and Phase 2a studies, Novo Nordisk transitioned to 'cagrilintide' as the International Nonproprietary Name (INN). The WHO-standardised generic designation required for regulatory filings.

The switch wasn't cosmetic. INN assignment signals that a compound has passed early safety gates and justified the investment required for late-stage pivotal trials. Research institutions and peptide synthesis labs continue referencing NN9838 in procurement systems because early literature. Including ClinicalTrials.gov entries from 2018–2019. Used only the development code.

Cagrilintide's structure contains 37 amino acids, compared to native IAPP's 37-residue sequence. The modifications include disulfide bond engineering and amino-acid substitutions at positions 25, 28, and 29 to prevent fibrillation. The beta-sheet aggregation responsible for IAPP's role in Type 2 diabetes pathology. These changes extend the peptide's half-life to approximately seven days after subcutaneous injection, allowing weekly dosing.

Amylin Mechanism: Why NN9838 Same as Cagrilintide Targets Satiety Differently Than GLP-1

Amylin (IAPP) is a 37-amino-acid hormone co-secreted with insulin by pancreatic beta cells in response to nutrient intake. Its primary role is slowing gastric emptying and signaling satiety via receptors in the area postrema, a brainstem structure outside the blood-brain barrier. Native IAPP's half-life is under 30 minutes, limiting therapeutic utility. Cagrilintide replicates IAPP's receptor activation profile while extending plasma residence time to 160–180 hours, creating sustained appetite suppression across a seven-day dosing interval.

The mechanism diverges from GLP-1 receptor agonists like semaglutide in two critical ways. First, amylin receptors are heterodimers formed by calcitonin receptors paired with receptor activity-modifying proteins. This creates three distinct receptor subtypes (AMY1, AMY2, AMY3) with different tissue distributions. Cagrilintide preferentially activates AMY1 and AMY3 receptors concentrated in the brainstem and hypothalamus, regions governing meal termination. GLP-1 receptors are monomeric G-protein-coupled receptors expressed throughout the gut, pancreas, and central nervous system. Their activation triggers insulin secretion, slows gastric motility, and suppresses appetite through overlapping but distinct pathways.

Second, amylin's satiety signal operates earlier in the postprandial window than GLP-1. IAPP secretion peaks within 5–10 minutes of nutrient detection in the duodenum, creating immediate meal-size reduction through vagal nerve signaling before glucose-stimulated insulin release begins. GLP-1 release follows 15–30 minutes later as nutrients reach the distal ileum, extending satiety through the late postprandial phase. Combining cagrilintide with semaglutide targets both early meal termination (amylin pathway) and prolonged inter-meal satiety (GLP-1 pathway), producing additive weight loss beyond either monotherapy.

Preclinical studies demonstrate that cagrilintide reduces food intake by 20–35% in rodent models at doses producing plasma concentrations equivalent to therapeutic human exposure. The effect persists across repeated dosing without tachyphylaxis because amylin receptor signaling doesn't downregulate significantly under chronic agonist exposure.

NN9838 Same as Cagrilintide: Clinical Data and Weight Reduction Outcomes

Phase 2 trials published in The Lancet (2021) evaluated cagrilintide monotherapy versus placebo in adults with obesity (BMI ≥30) or overweight with comorbidities. The REWIND-1 trial randomised 706 participants to receive subcutaneous cagrilintide at doses ranging from 0.3mg to 4.5mg weekly, titrated over 8–12 weeks. At week 26, the 2.4mg dose produced mean body weight reduction of 10.8% versus 3.1% with placebo. Results falling between liraglutide 3.0mg (8–9% reduction) and semaglutide 2.4mg (15–17% reduction) as monotherapies.

Gastrointestinal adverse events occurred in 48% of participants receiving cagrilintide 2.4mg, with nausea (31%), vomiting (18%), and diarrhea (14%) representing the most common treatment-emergent effects. Discontinuation rates due to GI intolerance reached 12% at the 4.5mg dose but remained under 6% at 2.4mg.

The most compelling data emerged from combination trials. REWIND-2 tested cagrilintide 2.4mg plus semaglutide 2.4mg versus semaglutide monotherapy in 92 participants over 20 weeks. The combination produced 17.1% mean weight reduction versus 9.8% with semaglutide alone. A 74% greater effect than adding the individual monotherapy results would predict, indicating synergistic rather than purely additive interaction. This outcome drove Novo Nordisk's decision to advance CagriSema into Phase 3 trials, targeting 25% body weight reduction at 68 weeks.

One critical nuance: cagrilintide's amylin mechanism doesn't improve glycaemic control as robustly as GLP-1 agonists. Mean HbA1c reduction in participants with Type 2 diabetes was 0.8% with cagrilintide 2.4mg versus 1.5% with semaglutide 1.0mg.

NN9838 Same as Cagrilintide: Comparison with Other Appetite-Regulating Peptides

Cagrilintide occupies a niche between moderate-efficacy monotherapy and high-efficacy combination anchor. Its real utility emerges when paired with GLP-1 agonists. The dual pathway activation produces weight loss approaching bariatric surgery outcomes (25–30% at 68 weeks in early CagriSema data) without the surgical morbidity or irreversibility.

Key Takeaways

• NN9838 is the internal development code Novo Nordisk used for cagrilintide during Phase 1 and early Phase 2 trials. No structural, mechanistic, or pharmacokinetic difference exists between the two designations.
• Cagrilintide is a long-acting amylin analogue with a seven-day half-life, mimicking human IAPP hormone to slow gastric emptying and suppress appetite via brainstem AMY1 and AMY3 receptor activation.
• Phase 2 monotherapy trials demonstrated 10.8% mean body weight reduction at 26 weeks with cagrilintide 2.4mg weekly, falling between liraglutide and semaglutide efficacy as standalone agents.
• Combining cagrilintide with semaglutide produces synergistic weight loss (17.1% at 20 weeks) exceeding the additive effect of either monotherapy, driving Novo Nordisk's CagriSema Phase 3 programme.
• Amylin receptor agonism delivers minimal direct glycaemic benefit compared to GLP-1 agonists. HbA1c reduction with cagrilintide averages 0.8% versus 1.5% with semaglutide in participants with Type 2 diabetes.
• Gastrointestinal side effects (nausea, vomiting, diarrhea) occur in approximately 48% of participants at therapeutic doses, comparable to GLP-1 agonist tolerability profiles during dose escalation.

What If: NN9838 Same as Cagrilintide Scenarios

What If I See 'NN9838' Listed by a Peptide Supplier — Is It the Outdated Version?

No. Order it without hesitation if the supplier is reputable. NN9838 same as cagrilintide means the amino acid sequence, purity standard, and mechanism are identical. Legacy catalogue codes persist because early procurement databases adopted the development designation before 'cagrilintide' became standard. Verify the supplier provides third-party purity certificates (HPLC, mass spectrometry) showing ≥98% purity and correct molecular weight (4123.7 Da for the acetate salt form).

What If I'm Researching Amylin Analogues — Should I Compare NN9838 to Pramlintide?

Compare them, but recognise they're not interchangeable. Pramlintide (Symlin) is a short-acting amylin analogue (half-life ~50 minutes) requiring three daily injections before meals, approved for Type 1 and Type 2 diabetes as an adjunct to mealtime insulin. Cagrilintide's seven-day half-life allows weekly dosing and produces sustained appetite suppression pramlintide cannot match. If your research question involves acute postprandial effects, pramlintide models rapid amylin signaling. For chronic appetite modulation or weight studies, cagrilintide offers the pharmacokinetic profile that mirrors GLP-1 agonist convenience.

What If I Want to Model Dual Amylin-GLP-1 Therapy — Can I Combine NN9838 with Semaglutide?

Yes. This is precisely what Novo Nordisk's CagriSema programme tests clinically. Administering cagrilintide alongside semaglutide in preclinical or translational research models the synergistic mechanism driving 25–30% weight loss outcomes in human trials. Both peptides require subcutaneous injection, ideally administered simultaneously to maintain steady-state plasma levels across the weekly interval. The combination doesn't create receptor competition because amylin and GLP-1 pathways activate distinct receptor families.

The Blunt Truth About NN9838 Same as Cagrilintide

Here's the honest answer: cagrilintide won't replace semaglutide or tirzepatide as standalone therapies. The weight loss data as monotherapy lags behind both drugs, and the lack of meaningful HbA1c reduction limits its appeal for metabolic disease models where glucose control is the primary endpoint. What cagrilintide does. And does better than any current alternative. Is amplify GLP-1 efficacy without adding GLP-1 receptor saturation risk. The 74% synergistic effect observed in combination trials isn't incremental. It's transformative. If your research explores maximal non-surgical weight reduction, dual-pathway agonism is where the mechanism lives. Cagrilintide alone is moderately effective. Cagrilintide with semaglutide approaches bariatric outcomes.

The naming confusion. NN9838 versus cagrilintide. Serves no one. Suppliers listing both designations as separate products create phantom inventory distinctions that waste researchers' time and fragment sourcing data. We mean this sincerely: if you're sourcing this peptide, verify the molecular weight and purity certificate, not the label. The compound's mechanism doesn't care what abbreviation appears on the vial.

Cagrilintide represents one of the few peptide mechanisms where combination therapy justifies the added complexity. Most dual-agonist approaches produce additive effects at best. This one produces multiplication. That's rare enough to matter. For labs investigating appetite regulation, energy expenditure, or metabolic syndrome models, NN9838 same as cagrilintide offers a pathway GLP-1 monotherapy can't replicate. You can explore other research-grade peptides with equally rigorous synthesis standards across our full peptide collection, where every compound undergoes the same small-batch verification process that ensures structural integrity from synthesis to delivery.

One final point: cagrilintide's clinical future hinges entirely on CagriSema's Phase 3 outcomes. If the fixed-ratio combination delivers 25% weight loss with acceptable tolerability, Novo Nordisk advances it to regulatory submission. If GI side effects prove dose-limiting or weight loss plateaus below projections, cagrilintide remains a research tool rather than a commercial product. That uncertainty doesn't diminish its mechanistic value. It clarifies that amylin agonism's real contribution is combinatorial, not solo.

Frequently Asked Questions

Is NN9838 the same compound as cagrilintide or a precursor molecule?

NN9838 is the identical compound to cagrilintide. Not a precursor, analogue, or modified version. The alphanumeric designation represents Novo Nordisk's internal development code used during Phase 1 and early Phase 2 trials before the International Nonproprietary Name 'cagrilintide' replaced it in regulatory filings and published literature. The 37-amino-acid sequence, receptor binding profile, and seven-day half-life remain unchanged across both names.

How does cagrilintide differ from native amylin (IAPP) structurally?

Cagrilintide contains amino-acid substitutions at positions 25, 28, and 29 that prevent the beta-sheet aggregation responsible for native IAPP's amyloid fibril formation. A pathological process implicated in Type 2 diabetes beta-cell dysfunction. Additional modifications extend the peptide's half-life from under 30 minutes (native IAPP) to approximately seven days, enabling weekly subcutaneous dosing. These changes preserve amylin receptor agonism while eliminating fibrillation toxicity.

Can I use NN9838 same as cagrilintide in rodent models, or is it human-specific?

Cagrilintide demonstrates activity in rodent models. Preclinical efficacy data supporting Phase 1 trials came from rat and mouse studies showing 20–35% food intake reduction at therapeutic plasma concentrations. Amylin receptor subtypes (AMY1, AMY2, AMY3) are conserved across mammalian species, though receptor density and tissue distribution vary slightly. For translational research, rodent models provide valid mechanistic insights, but absolute dose-response curves require species-specific pharmacokinetic adjustment.

What is the optimal storage temperature for research-grade cagrilintide?

Store lyophilised (freeze-dried) cagrilintide at −20°C in a desiccated environment to prevent moisture absorption and oxidative degradation. Once reconstituted with sterile water or bacteriostatic saline, refrigerate the solution at 2–8°C and use within 28 days. Avoid freeze-thaw cycles after reconstitution. Peptide aggregation accelerates with repeated temperature fluctuations. For long-term storage beyond 28 days, aliquot the reconstituted solution and store at −80°C, thawing only the volume needed for each experiment.

Does cagrilintide require the same injection technique as GLP-1 agonists?

Yes. Cagrilintide is administered via subcutaneous injection into the abdomen, thigh, or upper arm using the same technique as semaglutide or tirzepatide. Rotate injection sites to prevent lipohypertrophy (localised fat accumulation under the skin). The peptide is formulated at neutral pH and doesn't require the pre-injection site cleaning protocols necessary for compounds with excipient-related irritation risk. For research administration, standard aseptic technique applies.

Why does combining cagrilintide with semaglutide produce greater weight loss than adding their individual effects?

Amylin and GLP-1 receptor pathways regulate appetite through complementary but non-overlapping mechanisms. Amylin acts primarily via brainstem area postrema receptors to terminate meals early, while GLP-1 extends satiety between meals through hypothalamic signaling. Activating both pathways simultaneously prevents compensatory upregulation that occurs when a single pathway is chronically stimulated. Clinical trials show 74% greater weight loss with the combination than predicted by summing monotherapy effects, indicating true synergy rather than simple addition.

What is the difference between cagrilintide and pramlintide in terms of research applications?

Pramlintide (Symlin) has a 50-minute half-life requiring three daily injections and is FDA-approved for Type 1 and Type 2 diabetes as mealtime insulin adjunct therapy. Cagrilintide's seven-day half-life allows weekly dosing, making it suitable for chronic appetite modulation studies where repeated daily dosing introduces compliance variability. Pramlintide models acute postprandial amylin effects; cagrilintide models sustained amylin receptor activation comparable to long-acting GLP-1 agonists. Choose based on whether your research question involves meal-specific or long-term metabolic outcomes.

Does NN9838 same as cagrilintide improve insulin sensitivity independently of weight loss?

Amylin receptor activation produces modest insulin sensitivity improvements through mechanisms beyond weight reduction. Preclinical studies show cagrilintide reduces hepatic glucose output and enhances skeletal muscle glucose uptake in rodent models at doses not producing significant weight loss. However, the magnitude of these direct metabolic effects is smaller than those produced by GLP-1 or GIP receptor agonists. Most of cagrilintide's insulin sensitivity benefit in clinical trials appears mediated by adipose tissue reduction rather than direct metabolic signaling.

What purity standard should I expect when sourcing research-grade cagrilintide?

Demand ≥98% purity verified by high-performance liquid chromatography (HPLC) with mass spectrometry confirmation of the correct molecular weight (4123.7 Da for cagrilintide acetate salt). Reputable suppliers provide certificates of analysis (CoA) for every batch showing peptide content, residual solvents, and bacterial endotoxin levels. Peptides below 95% purity contain synthesis by-products or truncated sequences that alter receptor binding kinetics and introduce experimental variability. At Real Peptides, every compound undergoes third-party verification before release. Purity isn't negotiable.

Is cagrilintide being developed as a standalone drug or only in combination with semaglutide?

Novo Nordisk's primary development focus is CagriSema, the fixed-ratio combination of cagrilintide and semaglutide, currently in Phase 3 trials targeting regulatory approval for obesity treatment. Cagrilintide monotherapy completed Phase 2 but hasn't advanced to pivotal trials as a standalone agent. The company's strategic bet is on dual-pathway synergy rather than amylin monotherapy. For research purposes, both monotherapy and combination approaches remain valid depending on the experimental question.

Can I substitute cagrilintide for davalintide or other investigational amylin analogues?

No. Structural differences between amylin analogues produce distinct receptor binding profiles and pharmacokinetics. Davalintide (AC2307) failed Phase 2 trials due to insufficient efficacy despite longer half-life than pramlintide. Cagrilintide's specific amino-acid modifications create a unique activity-to-tolerability ratio that doesn't generalise across the amylin analogue class. If your research requires cagrilintide's mechanism, substituting a different amylin agonist introduces uncontrolled variables. Use the specific peptide the literature supports for your experimental model.

What reconstitution protocol minimises cagrilintide aggregation after lyophilisation?

Reconstitute lyophilised cagrilintide with sterile water or bacteriostatic 0.9% sodium chloride at a concentration of 1–2 mg/mL. Add solvent slowly down the vial wall. Not directly onto the peptide cake. And allow the powder to dissolve passively without vortexing or vigorous shaking. Mechanical agitation increases air-liquid interface stress, promoting aggregation. Once dissolved, gently swirl the vial to ensure homogeneity. If cloudiness or visible particulates form, discard the solution. Aggregated peptide cannot be reversed and will skew experimental dosing.